Literature DB >> 20389130

Effects of angiotensin II on renal dopamine metabolism: synthesis, release, catabolism and turnover.

Marcelo R Choi1, Brenda M Lee, Cecilia Medici, Alicia H Correa, Belisario E Fernández.   

Abstract

BACKGROUND/AIMS: Dopamine (DA) uptake inhibition in the renal cortex, elicited by angiotensin II (ANG II), is mediated by AT(1) receptors and signals through the phospholipase C pathway and activation of protein kinase C and CaM-kinase II. By this indirect way, ANG II stimulates renal Na(+),K(+)-ATPase activity through DA intracellular reduction. In the present work, we continued to study different aspects of renal DA metabolism in DA-ANG II interaction, such as DA synthesis, release, catabolism and turnover.
METHODS: ANG II effects on DA synthesis, release, catabolism and turnover were measured in samples from the outer renal cortex of Sprague-Dawley rats.
RESULTS: ANG II reduced renal aromatic acid decarboxylate activity without affecting basal secretion of DA or its KCl-induced release. Moreover, ANG II enhanced monoamine oxidase activity without altering catechol-o-methyl transferase activity and increased DA turnover.
CONCLUSION: Current results as well as previous findings show that ANG II modifies DA metabolism in rat renal cortex by reducing DA uptake, decreasing DA synthesis enzyme activity and increasing monoamine oxidase activity, and DA turnover. Together, all these effects may reduce DA accumulation into renal cells and decrease its endogenous content and availability. This would prevent D1 receptor recruitment and stimulation, while diminishing DA inhibition of Na(+),K(+)-ATPase activity and stimulating sodium reabsorption.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20389130     DOI: 10.1159/000311522

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  6 in total

1.  Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury.

Authors:  Shilin Yang; Bing Yao; Yunfeng Zhou; Huiyong Yin; Ming-Zhi Zhang; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-14

2.  The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans.

Authors:  Aruna R Natarajan; Gilbert M Eisner; Ines Armando; Shaunagh Browning; John C Pezzullo; Lauren Rhee; Mustafa Dajani; Robert M Carey; Pedro A Jose
Journal:  J Am Soc Nephrol       Date:  2015-05-14       Impact factor: 10.121

3.  Human GRK4γ142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition.

Authors:  Zheng Wang; Chunyu Zeng; Van Anthony M Villar; Shi-You Chen; Prasad Konkalmatt; Xiaoyan Wang; Laureano D Asico; John E Jones; Yu Yang; Hironobu Sanada; Robin A Felder; Gilbert M Eisner; Matthew R Weir; Ines Armando; Pedro A Jose
Journal:  Hypertension       Date:  2015-12-14       Impact factor: 10.190

Review 4.  Signaling pathways involved in renal oxidative injury: role of the vasoactive peptides and the renal dopaminergic system.

Authors:  N L Rukavina Mikusic; M C Kravetz; N M Kouyoumdzian; S L Della Penna; M I Rosón; B E Fernández; M R Choi
Journal:  J Signal Transduct       Date:  2014-11-11

5.  Acute infusion of angiotensin II regulates organic cation transporters function in the kidney: its impact on the renal dopaminergic system and sodium excretion.

Authors:  Nicolás M Kouyoumdzian; Natalia L Rukavina Mikusic; Gabriel D Robbesaul; Susana B Gorzalczany; Andrea Carranza; Verónica Trida; Belisario E Fernández; Marcelo R Choi
Journal:  Hypertens Res       Date:  2020-09-16       Impact factor: 3.872

Review 6.  Atrial natriuretic peptide and renal dopaminergic system: a positive friendly relationship?

Authors:  Marcelo Roberto Choi; Natalia Lucía Rukavina Mikusic; Nicolás Martín Kouyoumdzian; María Cecilia Kravetz; Belisario Enrique Fernández
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.